ResearchMoz.us

ResearchMoz is the one stop online destination to find and buy market research reports and Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Thursday 8 August 2013

Meningococcal Vaccines- Brazil, Australia, United Kingdom, And Spain Drug Forecast and Market

ResearchMoz.us include new market research report"Meningococcal Vaccines- Brazil, Australia, United Kingdom, And Spain Drug Forecast and Market " to its huge collection of research reports.

1) Brazil Drug Forecast and Market

GlobalData predicts that market(http://www.researchmoz.us/pharmapoint-meningococcal-vaccines-brazil-drug-forecast-and-market-analysis-to-2022-report.html) share for private vaccine manufacturers to virtually disappear over the course of the forecast, with Brazil unleashing domestically-produced MenC conjugate vaccines that are more cost-effective for the government-funded healthcare system. These vaccines, which include a MenC conjugate vaccine and a heptavalent pediatric vaccine (DTP-Hib-HepB-IPV-MenC) are being developed and produced by government-sponsored institutions such as Bio-Manguinhos, Instituto Butantan, Fiocruz, and FUNED. Once they become widely available, these vaccines will quickly steal market share from private manufacturers because of their cost-effectiveness advantage.

2) Australia Drug Forecast and Market

GlobalData believes that relative patient(http://www.researchmoz.us/pharmapoint-meningococcal-vaccines-australia-drug-forecast-and-market-analysis-to-2022-report.html) share for the three MenC conjugate vaccines available in Australia will remain unchanged for the duration of the forecast period because Nuron Biotechs Meningitec, Novartis Menjugate, and Baxters NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Australia and therefore is not expected to change drastically during the forecast period.

3) United Kingdom Drug Forecast and Market

GlobalData has released its new(http://www.researchmoz.us/pharmapoint-meningococcal-vaccines-united-kingdom-drug-forecast-and-market-analysis-to-2022-report.html) Country report, PharmaPoint: Meningococcal Vaccines United Kingdom Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

4) Spain Drug Forecast and Market

GlobalData predicts that relative patient(http://www.researchmoz.us/pharmapoint-meningococcal-vaccines-spain-drug-forecast-and-market-analysis-to-2022-report.html) share for the three MenC conjugate vaccines will remain unchanged for the duration of the forecast period because Nuron Biotechs Meningitec, Novartis Menjugate kit, and Baxters NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Spain and therefore is not expected to change drastically during the forecast period. In addition, GlobalData believes that an expected change in the booster administration age, from two to 11 years of age, will not dramatically alter sales, although a small coverage rate decrease associated with the older age group may occur (MSSSI, 2013).


For More Information Kindly Contact:

0 comments:

Post a Comment